United Statesi December News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from United statesi december. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In United Statesi December Today - Breaking & Trending Today

Takeda's QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union | Vaccines

Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union ....

United States , Sri Lanka , Dominican Republic , Gary Dubin , Tomas Jelinek , European Commission Approved , European Union Eu Member States , European Union , European Commission , Berlin Centre For , Data Monitoring Committee , Dengue Tetravalent Vaccine , Individuals Four Years , Only Dengue Vaccine Approved , Individuals Regardless , Previous Dengue , United Statesi December , European Medicines Agency , Medicinal Products , Human Use , Global Vaccine Business Unit , Medical Director , Berlin Centre , Tropical Medicine , Scientific Director , Dengue Efficacy Study ,

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day | Small Molecules

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day ....

United States , Ikaros Aiolos , Cereblon Imi , Nello Mainolfi , A Alpha Bio , I Kymera Therapeutics Inc , University Of Washington , Development Program , York University , Kymera Discloses New , Unveils New Development Program , Provides Oncology Pipeline , Discovery Updates , Ascending Dose , United Statesi December , Kymera Therapeutics , Chief Executive , Portfolio Updates , Diffuse Largeb Cell Lymphoma , New York , Fierce Biotech , Boston Business Journal , Small Molecule , New Chemical Entity , Drug Delivery , Flow Release ,

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease | DNA RNA and Cells

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease ....

United States , Jagdeep Wahlia , Suyash Prasad , Ceroid Lipofuscinosis , Jagdeeps Walia , Head Of Research , I Taysha Gene Therapies Inc , Queen University , Development Of Taysha , European Commission , Drug Administration , Kingston Health Sciences Centre , European Union , University Of Rochester , Queen University In Ontario , Health Canada , Research Department Of Pediatrics , Taysha Gene Therapies Announces Initiation , Clinical Development , United Statesi December , Taysha Gene Therapies , Clinical Trial Application , Chief Medical Officer , Clinical Geneticist , Associate Professor Head , Medical Genetics ,

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 | Antibodies

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 ....

Jeff Miller , Beverly Hills , Gregory Berk , I Gt Biopharma Inc , Esmo Io Congress , University Of Minnesota , European Society For Medical Oncology , Oncology Io Congress , Activation Against Broad Spectrum , United Statesi December , European Society , Medical Oncology , Chief Medical Officer , Interim Chief Executive , Acute Myelogenous Leukemia , Myelodysplastic Syndrome , Engagers Display Robust , Poster Display Title , Tri Specific Killer Engager , Therapeutic Antibodies , Antibody Drug Conjugates , Biosimilar Antibodies , Biosuperior Antibodies , Antibody Fragments , Domain Antibodies ,

Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) | Small Molecules

Hits: 1013
The trial failed to meet its primary endpoint of complete remission (CR) rate
CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance
BOSTON, MA, USA I December 28, 2020 I Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced results of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine (AZA) versus AZA alone in
TP53 mutant myelodysplastic syndromes (MDS). The trial did not meet the predefined primary endpoint of complete remission (CR) rate. Analysis of the primary endpoint at this data cut demonstrated a higher CR rate in the experimental arm receiving eprenetapopt with AZA versus the control arm receiving AZA alone, but did not reach statistical significance. ....

United States , International Working Group , I Aprea Therapeutics Inc , European Commission , European Medicines Agency , Aprea Therapeutics Inc , Aprea Therapeutics Announces Results , Primary Endpoint , Myelodysplastic Syndromes , United Statesi December , Aprea Therapeutics , Eyal Attar , Chief Medical Officer , Breakthrough Therapy , Orphan Drug , Fast Track , ஒன்றுபட்டது மாநிலங்களில் , சர்வதேச வேலை குழு , நான் ஏப்ரல் சிகிச்சை இன்க் , ஐரோப்பிய தரகு , ஏப்ரல் சிகிச்சை இன்க் , ப்ரைமரீ இறுதிப்புள்ளி , ஏப்ரல் சிகிச்சை , கண் அத்தர் , தலைமை மருத்துவ அதிகாரி , திருப்புமுனை சிகிச்சை ,